Effectiveness and Safety of Apixaban Versus
Warfarin in Obese Patients With NVAF
Enrolled in Medicare and Veteran Affairs
Deitelzweig S, Sah J, Kang A, Russ C, Preib M, Dhamane AD, Ratiu A, Cato M, Alfred T, Levi E, and Di Fusco M.
Objective: To compare the risks of stroke/SE and MB among elderly obese patients (defined as BMI ≥30 kg/m2 or body weight ≥100 kg*) with NVAF initiating apixaban versus warfarin
